Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
18,320,557
-
Shares change
-
+659,515
-
Total reported value, excl. options
-
$388,394,891
-
Value change
-
+$15,022,269
-
Number of buys
-
36
-
Number of sells
-
-13
-
Price
-
$21.2
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q2 2021
56 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q2 2021.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18,320,557 shares
of 274,772,727 outstanding shares and own 6.67% of the company stock.
Largest 10 shareholders include FMR LLC (5,687,616 shares), BlackRock Inc. (2,966,771 shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO (1,391,190 shares), FRANKLIN RESOURCES INC (1,305,846 shares), Artal Group S.A. (1,040,882 shares), SANDS CAPITAL MANAGEMENT, LLC (724,873 shares), TimesSquare Capital Management, LLC (683,400 shares), Alphabet Inc. (640,882 shares), VANGUARD GROUP INC (628,644 shares), and TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500,000 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.